Tumor-Targeted IFNα Delivery Engineering Services
Creative Biolabs' services are specifically designed to address the central challenge of IFNα therapy: maximizing therapeutic benefit at the tumor site while ensuring safety. We provide advanced solutions that result in next-generation molecules capable of overcoming therapy resistance, enabling you to de-risk your preclinical pipeline significantly. Our integrated strategy focuses on precision targeting, which confines IFNα activity to the tumor microenvironment (TME), and biased agonism, which engineers selective IFNα signaling to enhance anti-tumor pathways while minimizing systemic toxicity pathways. This dual focus creates therapeutics with superior efficacy and a dramatically improved therapeutic index.
Background Featured Services What We Can Offer Workflow Publication Why Choose Us FAQs Customer Review Related Services Contact Us
The Critical Need for Precision in Type I Interferon Therapy
IFNα is a potent, pleiotropic cytokine vital for innate and adaptive anti-tumor immunity, promoting direct anti-proliferative effects, NK cell cytotoxicity, and dendritic cell function. However, the systemic use of recombinant IFNα faces severe limitations due to significant dose-limiting toxicities. These include profound flu-like symptoms, myelosuppression, and long-term functional exhaustion of hematopoietic stem/progenitor cells (HSPCs). These toxicities have severely restricted its clinical application, despite its immense potential in the oncology arsenal.
Our Featured Services
Anti-CD20 targeted IFNα Development
Creative Biolabs offers anti-CD20 targeted IFNα development to engineer immunocytokines that specifically deliver potent IFNα activity to B-cell malignancies, enhancing efficacy and reducing systemic toxicity.
Learn More →
Tumor Antigen/Microenvironment targeted IFNα Development
Creative Biolabs engineers IFNα for tumor antigen/microenvironment targeting. We minimize systemic toxicity and maximize localized anti-tumor efficacy using advanced conditional activation strategies.
Learn More →
Dendritic Cell targeted IFNα Development
Creative Biolabs offers dendritic cell targeted IFNα development to selectively activate antigen presentation, maximizing anti-tumor immunity while dramatically minimizing systemic toxicity.
Learn More →
Key Deliverables & Solutions Focused on Safety and Efficacy
Toxicity Mitigation and Therapeutic Index Expansion
We deliver rigorously tested, attenuated IFNα fusion proteins that show zero systemic morbidity in preclinical models. This groundbreaking safety profile allows for significantly higher, more effective dosing at the target site without the dose-limiting toxicities associated with native IFN.
TME Reprogramming for Enhanced Immunity
Our engineered constructs reverse tumor-induced immunosuppression by increasing the activation and maturation of dendritic cells (DCs). This cascade subsequently enhances CD8+ T cell infiltration and proliferation, effectively converting immunologically "cold" tumors into highly responsive "hot" tumors.
Overcoming Therapy Resistance
We provide validated molecules and gene vectors capable of overcoming acquired and primary resistance mechanisms that limit the effectiveness of standard treatments, including immune checkpoint blockade (ICB, such as anti-PD-1/PD-L1) and conventional radiation therapy (RT).
Optimized PK/PD Profile
Our engineering efforts balance two critical factors: serum half-life (using formats like full IgG) and deep tumor penetration, creating a molecule tailored precisely to your specific tumor antigen and delivery requirements.
If your current cytokine program is stalled due to safety concerns or poor efficacy, Creative Biolabs has the expertise to pivot your research. Reach out today to discuss your specific target and therapeutic needs.
Workflow
We execute our projects through a structured, transparent, and iterative workflow, designed for precision and reproducibility. This detailed process ensures a clear understanding of the project trajectory and milestones.
Publication
This study overcomes PD-1/PD-L1 checkpoint blockade resistance in advanced tumors by engineering a novel IFNα-anti-PD-L1 fusion protein. This "armed" antibody creates a feedforward antitumor response: it targets IFNα to the tumor site via PD-L1 binding, where it activates dendritic cells to re-invigorate T-cells. This process simultaneously upregulates PD-L1, enhancing the fusion protein's own accumulation. The strategy demonstrated potent efficacy in resistant mouse models, inducing complete tumor regression while minimizing systemic toxicity by restricting IFNα activity to the tumor microenvironment, presenting a promising next-generation immunotherapy.
Fig.1 Local IFNα delivery reverses resistance to PD-L1 blockade. 1
Why Choose Us?
Creative Biolabs is a leader in targeted cytokine engineering, offering a unique difference defined by several key advantages. Our unmatched expertise ensures functional restriction, achieving unprecedented safety margins by focusing on activity-on-target cytokines. We offer flexible dual delivery platforms, mastering both stable immunocytokines and local delivery (nanoparticles), allowing optimal strategy selection. Furthermore, our mechanistic validation focus goes beyond tumor shrinkage, providing rigorous data on TME reprogramming and DCs activation, with our proprietary methodologies being supported by published data for successful clinical translation.
Experience the Creative Biolabs Advantage - Get a Quote Today to Start Your Project.
FAQs
Q1: Is targeted IFNα delivery better than simple PEGylation for toxicity reduction?
A1: Yes. Our targeted delivery, especially AcTaferon engineering, involves attenuating the cytokine's intrinsic activity, which is then restored only upon binding the tumor-specific target, providing a far superior safety margin and therapeutic index.
Q2: Which delivery format is right for my project: Immunocytokine protein or AAV/NP gene vector?
A2: Immunocytokines (proteins) are excellent for quick systemic distribution and immediate effects. Gene vectors or nanoparticles are ideal if you require sustained, localized production or if you are targeting highly specific cell types like tumor-associated macrophages (TAMs).
Q3: What is the largest barrier to clinical translation for these targeted therapies?
A3: The main challenge remains robustly demonstrating safety and consistent biodistribution in large animal models before human trials. Our dedicated toxicity and biodistribution studies are specifically designed to generate high-quality PK/PD data.
Customer Reviews
-
Reduced Off-Target Effects
Using Creative Biolabs' services in our research has significantly improved the therapeutic window of our lead antibody-cytokine fusion. The elimination of IFN-related hematopoietic toxicity was critical for advancing our preclinical plan. – Dvid*Ger
-
Enhanced Combination Therapy
The immune activation and TME reprogramming profiling we received clearly demonstrated that the targeted IFNα could effectively convert our ICB non-responder mouse model into a highly sensitive responder. – Ma*Jes
Related Services
To achieve your ultimate goal of bringing a safe and effective therapeutic to market, you may require complementary services from Creative Biolabs.
Next Immunocytokine Engineering Development Service
Creative Biolabs specializes in immunocytokine engineering, fusing cytokines with targeting proteins to modulate localization, restrict activity to the TME, and enhance therapeutic efficacy while reducing systemic toxicity.
Learn More →
Cytokine Production Measurement Service
Creative Biolabs measures cytokine production using FC, ELISA, IHC, PCR, and IF with advanced instruments to better understand dysregulated cytokines in the TME.
Learn More →
How to Contact Creative Biolabs
Ready to discuss your specific project requirements, timelines, and the immediate next steps? Our specialized scientific team is standing by to provide a detailed, customized proposal and scientific consultation.
Contact Our Team for More Information and to Discuss Your Project
Reference
-
Liang, Yong, et al. "Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance." Nature communications 9.1 (2018): 4586. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1038/s41467-018-06890-y
